These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33179892)

  • 1. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
    Semenya AM; Wilson SA
    Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of Semaglutide.
    Smits MM; Van Raalte DH
    Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral semaglutide (Rybelsus) for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Oct; 61(1583):166-168. PubMed ID: 31770356
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.
    Scheen AJ
    Lancet Diabetes Endocrinol; 2020 May; 8(5):350-352. PubMed ID: 32333865
    [No Abstract]   [Full Text] [Related]  

  • 5. Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
    Blakely KK; Weaver K
    Nurs Womens Health; 2020 Oct; 24(5):370-376. PubMed ID: 32890462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice].
    Karásek D
    Vnitr Lek; 2022; 68(2):89-95. PubMed ID: 36208922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
    Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical guidance for use of oral semaglutide in primary care: a narrative review.
    Morales J; Shubrook JH; Skolnik N
    Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New drug for type 2 diabetes: introduction of oral Semaglutide (Rybelsus
    Miyasaka K
    Nihon Yakurigaku Zasshi; 2022; 157(2):146-154. PubMed ID: 35228448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The glucagon-like peptide-1 receptor-agonist semaglutide].
    Boje AD; Juhl CR; Torekov SS; Madsbad S
    Ugeskr Laeger; 2019 Oct; 181(41):. PubMed ID: 31610830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.
    Kalra S; Kalhan A; Berard L
    Postgrad Med; 2020 Nov; 132(8):663-666. PubMed ID: 32781867
    [No Abstract]   [Full Text] [Related]  

  • 13. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
    Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
    Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research digest: pioneering an oral GLP-1 receptor agonist.
    Atkinson MA; Powers AC
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):897. PubMed ID: 31748168
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
    Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
    Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
    Giugliano D; Esposito K; De Nicola L
    Diabetes Obes Metab; 2024 Nov; 26(11):4813-4815. PubMed ID: 39219442
    [No Abstract]   [Full Text] [Related]  

  • 17. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
    Brunton SA; Mosenzon O; Wright EE
    Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
    Simó R; Hernández C
    Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What the SELECT trial of semaglutide means for clinicians.
    Sattar N; Lee MMY; McGuire DK
    Nat Med; 2024 Jul; 30(7):1830-1831. PubMed ID: 38796654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.